*Sponsored
Jeff Ackerman Initiates Coverage On (TCRT) Starting Tomorrow Morning
—Monday, July 14, 2025
Limited Float Under 1.6M Shares Gives (TCRT) High Sensitivity Potential To
Shifts In Demand.
(TCRT) Recently Moved Approximately 171% In Less Than Two Months.
(TCRT) Triggers 100% Bullish Signals On Barchart.
(TCRT)'s Non-G.L.P-1 Strategy Stands Out In A Sector Projected To Hit $324.5B.
Take A Look At (TCRT) Before Tomorrow Morning…
July 13, 2025 Tomorrow's Radar | See Why (TCRT) Will Be Topping Monday's Watchlist Dear Reader, In a sector often dominated by hormonal manipulation, injectables, and sky-high costs, one company is taking a radically different approach—and it's doing so with scientific precision and strategic discipline. Alaunos Therapeutics, Inc. (Nasdaq: TCRT) has shifted its focus in recent quarters toward one of the most urgent global health challenges: obe-sity and metabolic disorders. And while it may still be preclinical, the company's direction—and the distinctiveness of its lead program—warrants a closer look. But keep in mind, (TCRT) has a very limited float with Yahoo reporting less than 1.6M shares listed as available to the public. Small floats could lead to the potential for big swings if demand begins to shift. And we've already seen what that can look like. From May 1 to June 27, (TCRT) moved approximately 171% in under two months—from $2.02 to $5.48. 
As of Friday, (TCRT) was trending near or above all of Barchart's major moving averages, including its 5-day, 20-day, 50-day, 100-day, and 200-day metrics. Even more exciting, Barchart's Technical Opinion tool is now registering a full 100% bullish rating across the board—from Trend Seeker®, to short-, medium-, and long-term indicators. If this momentum holds—and with key data milestones approaching—(TCRT) could be one little-known company worth keeping on your radar. Moving Beyond the G.L.P-1 Paradigm
The last few years have seen massive attention on G.L.P-1 receptor agonists, which have recently become the gold standard in the market. But these treatments come with caveats: cost, accessibility, and most notably, their effects on lean muscle mass and long-term metabolic health. (TCRT) isn't following the crowd. Its small molecule obe-sity program—anchored by ALN1001—is being developed as an oral compound that does not rely on hormonal pathways. The company's in vitro testing, initiated in late 2024, is currently evaluating how ALN1001 and its derivatives impact key genes tied to lipid metabolism, thermogenesis, and energy regulation. 
In simpler terms: (TCRT) is looking to target fat and energy pathways without triggering the hormonal side effects that complicate many existing treatments. The results of this ongoing in vitro study are expected to be available by early Q2 2025 and could provide key validation for next steps. According to company statements, compounds showing strong promise in improving metabolic activity and limiting fat accumulation may be advanced to rodent models of obe-sity as early as Q3 2025. Precision Over Hype: A Focused Development Path
Rather than rushing forward with unproven claims, (TCRT)is following a methodical and widely accepted route. The path forward includes: - In vitro gene expression and lipid metabolism testing (in progress)
- Preclinical di-et-induced obe-sity (DIO) mouse model testing, targeted for Q3 2025
- Potential IND-enabling studies, depending on results and partnerships
This disciplined roadmap reflects a company that understands both the regulatory environment and the biological complexity of metabolic health. A Strategic Manufacturing Model
(TCRT) has aligned with an experienced contract development and manufacturing organization (CDMO) to handle its active pharmaceutical ingredient (API) production. This outsourcing strategy minimizes overhead while maintaining high manufacturing standards—a smart move for a company in a capital-conscious preclinical phase. A Market That's Far From Saturated
The global branded obe-sity treatment segment was valued at around $6B in 2023, with projections initially suggesting a sharp rise to approximately $105B by 2030. Now, according to a 2025 Morgan Stanley report, the peak potential for this market could reach as high as $150B by 2035, reflecting growing demand, scientific momentum, and expanded patient access. Parallel to this, the global G.L.P-1 receptor agonist market is projected to reach $324.5B by 2035, representing a 4.9X expansion over the next decade. This category alone is reshaping the broader metabolic health landscape. Yet despite this explosive growth, differentiated, accessible, and non-invasive treatments remain scarce—especially for those seeking alternatives to injectable, hormone-based therapies. But despite this explosive growth outlook, differentiated, accessible, and non-invasive treatments remain scarce. This is where (TCRT)'s potential impact becomes most compelling. Its focus on an oral, small molecule therapeutic—with no reliance on hormone mimicry—places it in a rare category. If ALN1001 can show success in preclinical and early-stage studies, it may represent a new class of metabolic health interventions. Past Experience, Present Focus
While (TCRT) previously pursued advanced T-cell receptor therapies for oncology—partnering with institutions such as The University of Texas MD Anderson Cancer Center—the company made a strategic decision in 2023 to sunset those programs. The move, driven by the high costs of clinical development and shifting capital dynamics, allowed (TCRT) to focus its attention and resources on its obe-sity and metabolic pipeline. This pivot wasn't a retreat—it was a realignment. And it left (TCRT) with a valuable legacy: - A scientific team with advanced experience in cell therapy, gene modulation, and immune-oncology
- Established relationships with elite research institutions
- Ongoing access to proprietary non-viral gene delivery technologies and TCR intellectual property, preserved through licensing and R&D agreements
Protecting the Pipeline: Intellectual Property Positioning
As of December 2024, (TCRT) held six patent families related to its prior TCR programs. While no patents have been issued yet, the company has signaled intentions to pursue protection of its emerging small molecule obe-sity pipeline through a combination of owned and licensed filings, trade secrets, and confidentiality agreements. The company also retains long-term collaboration rights and perpetual licenses for key MD Anderson-originated technologies—positioning it well to navigate future scientific or commercial developments. Regulatory Awareness and Strategic Optionality
(TCRT) is advancing in a space governed by complex regulatory standards, particularly in the U.S., where FDA approvals follow a rigorous multi-phase process. The company has shown clear alignment with industry best practices for preclinical development and has outlined a viable roadmap through IND-enabling studies, if early data supports advancement. In parallel, (TCRT) continues to explore multiple strategic options. These may include partnerships, co-development deals, or other corporate transactions designed to align its platform with capital and infrastructure required for scaling. Bottom Line
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) isn't rushing the process—and that's a good thing. In an obe-sity treatment landscape crowded with injectables and copycat approaches, this company is quietly developing something structurally different, scientifically targeted, and potentially transformative. The second half of 2025 could become a pivotal window as in vitro results and preclinical decisions emerge. For those closely tracking innovation in metabolic health, Alaunos (Nasdaq: TCRT) is one name to keep firmly on the radar. 7 Reasons Why (TCRT) is Topping Our Watchlist Tomorrow Morning
—Monday, July 14, 2025…
1. Limited Float: with fewer than 1.6M shares available to the public reported by Yahoo, (TCRT) sits in a category where it could witness the potential for big moves if demand begins to shift. 2. Recent Momentum: from May 1 to June 27, (TCRT) moved approximately 171%— from $2.02 to $5.48 in under two months. 3. Technical Signals: as of Friday, (TCRT) was trending above all major moving averages tracked by Barchart and triggering a 100% bullish reading across short-, medium-, and long-term signals. 4. Distinct Mechanism Focus: unlike many in the obesity space, (TCRT) is developing an oral small molecule therapeutic that avoids hormonal manipulation and may help preserve lean muscle mass. 5. Strategic Manufacturing Setup: (TCRT) has outsourced API production to a specialized CDMO, maintaining scalability while reducing infrastructure costs in its preclinical phase. 6. Positioned Within Expansion: with the global G.L.P-1 market projected to reach $324.5B by 2035 and the broader obesity market potentially hitting $150B, (TCRT)'s unique non-G.L.P-1 approach places it in a rapidly growing sector with limited oral alternatives. 7. Scientific Legacy Depth: although now focused on metabolic health, (TCRT) retains deep institutional partnerships, advanced gene modulation expertise, and proprietary technology assets carried forward from its previous work in T-cell receptor therapies. Take A Look At (TCRT) Before Tomorrow Morning…
With its tightly held float, accelerating momentum, and a differentiated approach in one of the fastest-growing health markets, Alaunos Therapeutics, Inc. (Nasdaq: TCRT) is beginning to attract attention for all the right reasons. From its methodical preclinical roadmap to its non-hormonal strategy in a category crowded with injectables, (TCRT) stands out as one to watch closely—especially with technical signals flashing strength across every major timeframe. We will have all eyes on (TCRT) tomorrow morning. Take a look at (TCRT) before you call it a night. Also, keep a lookout for my morning update. Have a good night. Sincerely,
Jeff Ackerman
Managing Editor
Stock News Trends | 
Tidak ada komentar:
Posting Komentar